Novavax Inc vs Oklo Inc — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while Oklo Inc trades at $45.8 (market cap $8.74B). The key difference: Oklo Inc is far larger — about 6.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | OKLO | |
|---|---|---|
Market Cap | $1.31B | $8.74B |
Sector | Health | Technology |
52-Week High | $11.19 | $174.14 |
52-Week Low | $6.22 | $36.84 |
Enterprise Value | $889.30M | $6.28B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
OKLO trades at $46.41, up 4.32% over 24 hours, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses, with a net income margin of -12,625.54% in 2026. Recent milestones include achieving first criticality at its Groves isotope reactor, though cash burn remains high as it advances Aurora nuclear projects.
Outlook is speculative with high growth potential in nuclear energy infrastructure, but risks include persistent losses, execution challenges, and reliance on financing. Analyst sentiment is strongly bullish (76.9% buy ratings), yet investors must weigh the long-term payoff against near-term financial instability and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →